Australian biotech market watch 16/10/09
Friday, 16 October, 2009
It looks like the rally experienced by the All Ordinaries this week has finally begun to falter, led by a slip in bank stocks. As of 3pm this afternoon the All Ords was at 4,846, down 16 points for the day.
Heath stock fared a little better, with the S&P/ASX 200 Health Care index rising in the morning and dropping back to its open around 8,509.
Biota Holdings (ASX:BTA) continues its prodigious run, up another 15c today, to $3.42. Just for the record, Biota is up 918% YTD. Makes you think.
Primary Health Care (ASX:PRY) also had a positive day, lifting by 15c, or 2.5%, to $6.25, recovering some of the losses experienced during the week.
Pharmaceutical company, Acrux (ASX:ACR), developers of testosterone deficiency treatment, Axiron, bumped up 5c to $1.83.
ResMed (ASX:RMD) managed to put on 10c to $5.31, up 1.7%, after a week of ups and downs.
Sonic Health Care (ASX:SHL) continued its gains from Thursday, up 1% today to $13.85.
Cochlear (ASX:CHO) remains mainly steady, although a slight afternoon dip as shaved 59c from it stock, to $64.88. Blackmores (ASX:BKL) also shed 0.5% to $21.70.
Healthcare products specialist, Ansell (ASX:ANN), has maintained much of its gains received mid-week after it announced earnings were higher than expected for this quarter, dipping slightly to $10.68 today from its high of $10.95 on Wednesday.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
